These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35949125)
1. Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy. Balcıoğlu AS; Çelik E; Şahin M; Göçer K; Aksu E; Aykan AÇ Anatol J Cardiol; 2022 Nov; 26(11):832-840. PubMed ID: 35949125 [TBL] [Abstract][Full Text] [Related]
2. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Sympathetic Nervous System Activity Detected by Sympathetic Activity Index and LF/HF Ratio in Patients with Type 2 Diabetes Mellitus. Balcıoğlu AS; Çelik E; Aksu E; Aykan AÇ Turk Kardiyol Dern Ars; 2022 Sep; 50(6):415-421. PubMed ID: 35976237 [TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). Ang L; Kidwell KM; Dillon B; Reiss J; Fang F; Leone V; Mizokami-Stout K; Pop-Busui R J Diabetes Complications; 2021 Aug; 35(8):107949. PubMed ID: 34024686 [TBL] [Abstract][Full Text] [Related]
5. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116 [TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Vivian EM Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411 [TBL] [Abstract][Full Text] [Related]
7. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931 [TBL] [Abstract][Full Text] [Related]
8. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. Iacobellis G; Gra-Menendez S Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644 [TBL] [Abstract][Full Text] [Related]
9. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600 [TBL] [Abstract][Full Text] [Related]
12. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195 [TBL] [Abstract][Full Text] [Related]
13. Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. Hamaoka T; Murai H; Hirai T; Sugimoto H; Mukai Y; Inoue O; Takashima S; Kato T; Takata S; Usui S; Sakata K; Kawashiri MA; Takamura M J Am Heart Assoc; 2021 Nov; 10(22):e022637. PubMed ID: 34719241 [TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Nicholson MK; Ghazal Asswad R; Wilding JP Expert Opin Pharmacother; 2021 Dec; 22(17):2303-2310. PubMed ID: 34281456 [TBL] [Abstract][Full Text] [Related]
15. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Shin Y; Choi H; Lim S Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498 [TBL] [Abstract][Full Text] [Related]
16. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. Yabiku K; Nakamoto K; Tsubakimoto M J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424 [TBL] [Abstract][Full Text] [Related]
17. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Packer M Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418 [No Abstract] [Full Text] [Related]
18. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus. Davis PN; Ndefo UA; Oliver A J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661 [TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Calado J IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222 [TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]